Prefrontal cortical circuits in schizophrenia.

[1]  Takanori Hashimoto,et al.  Protracted Developmental Trajectories of GABA A Receptor α1 and α2 Subunit Expression in Primate Prefrontal Cortex , 2009, Biological Psychiatry.

[2]  K. Deisseroth,et al.  Parvalbumin neurons and gamma rhythms enhance cortical circuit performance , 2009, Nature.

[3]  M. Rasband,et al.  Postnatal development of synaptic structure proteins in pyramidal neuron axon initial segments in monkey prefrontal cortex , 2009, The Journal of comparative neurology.

[4]  G. Sugranyes,et al.  Cannabis use and age of diagnosis of schizophrenia , 2009, European Psychiatry.

[5]  D. Lewis,et al.  Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. , 2009, The Journal of clinical investigation.

[6]  B. Alger,et al.  Synaptic Cross Talk between Perisomatic-Targeting Interneuron Classes Expressing Cholecystokinin and Parvalbumin in Hippocampus , 2009, The Journal of Neuroscience.

[7]  David A. Lewis,et al.  Selective Alterations in Postsynaptic Markers of Chandelier Cell Inputs to Cortical Pyramidal Neurons in Subjects with Schizophrenia , 2009, Neuropsychopharmacology.

[8]  R. Cho,et al.  Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects , 2009, Neuropsychopharmacology.

[9]  Ekaterina A. Placzek,et al.  Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown , 2008, Neuropharmacology.

[10]  Sarah E. Forster,et al.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. , 2008, The American journal of psychiatry.

[11]  Peter B. Jones,et al.  Effects of cannabis use on outcomes of psychotic disorders: systematic review , 2008, British Journal of Psychiatry.

[12]  D. Lewis,et al.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. , 2008, Schizophrenia bulletin.

[13]  P. Penzes,et al.  Dendritic spine dynamics – a key role for kalirin-7 , 2008, Trends in Neurosciences.

[14]  G. Tononi,et al.  Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. , 2008, American Journal of Psychiatry.

[15]  David A Lewis,et al.  Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. , 2008, Archives of general psychiatry.

[16]  E. P. Gardner,et al.  Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex , 2008, Nature Reviews Neuroscience.

[17]  H. M. Morris,et al.  Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. , 2008, Cerebral cortex.

[18]  M. McInnis,et al.  Psychiatric genetics: progress amid controversy , 2008, Nature Reviews Genetics.

[19]  R. Fields,et al.  White matter in learning, cognition and psychiatric disorders , 2008, Trends in Neurosciences.

[20]  D. Barch,et al.  The Cognitive Neuroscience of Working Memory: Relevance to CNTRICS and Schizophrenia , 2008, Biological Psychiatry.

[21]  D. Javitt,et al.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.

[22]  M. Palkovits,et al.  Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain , 2008, Neuroscience.

[23]  M. Rasband,et al.  Spectrin and Ankyrin-Based Cytoskeletons at Polarized Domains in Myelinated Axons , 2008, Experimental biology and medicine.

[24]  David A Lewis,et al.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. , 2008, The American journal of psychiatry.

[25]  A. Zaitsev,et al.  Functional maturation of excitatory synapses in layer 3 pyramidal neurons during postnatal development of the primate prefrontal cortex. , 2008, Cerebral cortex.

[26]  D. Dietrich,et al.  The myelin-pathogenesis puzzle in schizophrenia: a literature review , 2008, Molecular Psychiatry.

[27]  H. M. Morris,et al.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia , 2008, Molecular Psychiatry.

[28]  J. Callicott,et al.  Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. , 2007, Cerebral cortex.

[29]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[30]  Peter B. Jones,et al.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.

[31]  J. Lieberman,et al.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[32]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[33]  R. Drake,et al.  Schizophrenia and co-occurring substance use disorder. , 2007, The American journal of psychiatry.

[34]  J. Meador-Woodruff,et al.  NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.

[35]  C. Carter,et al.  Impairments in frontal cortical γ synchrony and cognitive control in schizophrenia , 2006, Proceedings of the National Academy of Sciences.

[36]  W. Singer,et al.  Neural Synchrony in Brain Disorders: Relevance for Cognitive Dysfunctions and Pathophysiology , 2006, Neuron.

[37]  G. Fischbach.  Schizophrenia: signals from the other side , 2006, Nature Medicine.

[38]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[39]  T. Hashimoto,et al.  Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia , 2006, Molecular Psychiatry.

[40]  T. Freund,et al.  Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses , 2006, The Journal of Neuroscience.

[41]  Masahiko Watanabe,et al.  Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  Masahiko Watanabe,et al.  The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum , 2006, The Journal of Neuroscience.

[43]  S. Hutton,et al.  Comorbid substance use and age at onset of schizophrenia , 2006, British Journal of Psychiatry.

[44]  David A Lewis,et al.  Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. , 2006, Cerebral cortex.

[45]  R. Poulton,et al.  Cannabis and psychosis , 2006, BMJ : British Medical Journal.

[46]  S. Haber,et al.  Prefrontal Cortical Projections to the Midbrain in Primates: Evidence for a Sparse Connection , 2006, Neuropsychopharmacology.

[47]  M. Chee,et al.  fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. , 2005, The American journal of psychiatry.

[48]  Tyrone D. Cannon,et al.  Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. , 2005, Archives of general psychiatry.

[49]  David A Lewis,et al.  Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. , 2005, The American journal of psychiatry.

[50]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[51]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[52]  Jonathan D. Cohen,et al.  Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. , 2005, American Journal of Psychiatry.

[53]  R. McCarley,et al.  Neural synchrony indexes disordered perception and cognition in schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Pistis,et al.  Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons , 2004, The Journal of Neuroscience.

[55]  M. Egan,et al.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.

[56]  Priscilla Wu,et al.  Ankyrin-Based Subcellular Gradient of Neurofascin, an Immunoglobulin Family Protein, Directs GABAergic Innervation at Purkinje Axon Initial Segment , 2004, Cell.

[57]  T. Freund,et al.  Segregation of two endocannabinoid‐hydrolyzing enzymes into pre‐ and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala , 2004, The European journal of neuroscience.

[58]  Paul J. Harrison,et al.  Catechol-O-Methyltransferase Inhibition Improves Set-Shifting Performance and Elevates Stimulated Dopamine Release in the Rat Prefrontal Cortex , 2004, The Journal of Neuroscience.

[59]  Ralitza Gueorguieva,et al.  The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis , 2004, Neuropsychopharmacology.

[60]  David A Lewis,et al.  Cortical connections of the lateral mediodorsal thalamus in cynomolgus monkeys , 2004, The Journal of comparative neurology.

[61]  A. Sampson,et al.  Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: Volume, neuron number, and cell types , 2004, The Journal of comparative neurology.

[62]  Patricia S. Goldman-Rakic,et al.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.

[63]  Victor Vostrikov,et al.  Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. , 2004, The American journal of psychiatry.

[64]  R. Kahn,et al.  Cannabis use and age at onset of schizophrenia. , 2004, The American journal of psychiatry.

[65]  Bita Moghaddam,et al.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia , 2004, Psychopharmacology.

[66]  Paul J. Harrison,et al.  Catechol‐o‐methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression , 2004, Synapse.

[67]  M. Egan,et al.  Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. , 2003, The American journal of psychiatry.

[68]  Marc W Howard,et al.  Gamma oscillations correlate with working memory load in humans. , 2003, Cerebral cortex.

[69]  Miles A Whittington,et al.  Interneuron Diversity series: Inhibitory interneurons and network oscillations in vitro , 2003, Trends in Neurosciences.

[70]  William Byne,et al.  Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients with schizophrenia. , 2003, Archives of general psychiatry.

[71]  A. Sampson,et al.  Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia , 2003, The Journal of Neuroscience.

[72]  T. Freund,et al.  Role of endogenous cannabinoids in synaptic signaling. , 2003, Physiological reviews.

[73]  Marc Laruelle,et al.  Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia , 2003, Neuropsychopharmacology.

[74]  Daniel R Weinberger,et al.  Catechol O-Methyltransferase (COMT) mRNA Expression in the Dorsolateral Prefrontal Cortex of Patients with Schizophrenia , 2003, Neuropsychopharmacology.

[75]  Paul J. Harrison,et al.  Low medial and lateral right pulvinar volumes in schizophrenia: a postmortem study. , 2003, The American journal of psychiatry.

[76]  Peter Falkai,et al.  Volumes of association thalamic nuclei in schizophrenia: a postmortem study , 2003, Schizophrenia Research.

[77]  D. Manoach.  Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings , 2003, Schizophrenia Research.

[78]  D. Yurgelun-Todd,et al.  Early-onset cannabis use and cognitive deficits: what is the nature of the association? , 2003, Drug and alcohol dependence.

[79]  M. Vreugdenhil,et al.  Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. , 2003, Journal of neurophysiology.

[80]  David A Lewis,et al.  Reduced Pyramidal Cell Somal Volume in Auditory Association Cortex of Subjects with Schizophrenia , 2003, Neuropsychopharmacology.

[81]  P. Somogyi,et al.  Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo , 2003, Nature.

[82]  S. Sesack,et al.  Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia , 2002, Physiology & Behavior.

[83]  Glyn Lewis,et al.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study , 2002, BMJ : British Medical Journal.

[84]  A. Sampson,et al.  Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. , 2002, Cerebral cortex.

[85]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Sedvall,et al.  PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.

[87]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[88]  Thomas Babor,et al.  Cognitive functioning of long-term heavy cannabis users seeking treatment. , 2002, JAMA.

[89]  A. Lichtman,et al.  Endocannabinoids in cognition and dependence. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[90]  A. Sampson,et al.  Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. , 2001, Archives of general psychiatry.

[91]  J. Sweeney,et al.  Thalamic volumes in patients with first-episode schizophrenia. , 2001, The American journal of psychiatry.

[92]  K. N. Dudkin,et al.  Neurophysiological Correlates of Delayed Visual Differentiation Tasks in Monkeys: the Effects of the Site of Intracortical Blockade of NMDA Receptors , 2001, Neuroscience and Behavioral Physiology.

[93]  J. Cohen,et al.  Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. , 2001, Archives of general psychiatry.

[94]  German Barrionuevo,et al.  Synaptic targets of the intrinsic axon collaterals of supragranular pyramidal neurons in monkey prefrontal cortex , 2001, The Journal of comparative neurology.

[95]  L. Siever,et al.  Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. , 2001, Archives of general psychiatry.

[96]  A. Sampson,et al.  GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. , 2001, The American journal of psychiatry.

[97]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[98]  R. Hoffman,et al.  Schizophrenia as a disorder of developmentally reduced synaptic connectivity. , 2000, Archives of general psychiatry.

[99]  A. Sampson,et al.  Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.

[100]  P. Goldman-Rakic,et al.  Destruction and Creation of Spatial Tuning by Disinhibition: GABAA Blockade of Prefrontal Cortical Neurons Engaged by Working Memory , 2000, The Journal of Neuroscience.

[101]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[102]  A Reichenberg,et al.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.

[103]  P. McKenna,et al.  Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor α-1 subunit messenger RNA and human GABA transporter-1 (hGAT-1) messenger RNA expression , 1999, Neuroscience.

[104]  G. Gigerenzer,et al.  Specific attentional dysfunction in adults following early start of cannabis use , 1999, Psychopharmacology.

[105]  P. Goldman-Rakic,et al.  The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.

[106]  Vann Bennett,et al.  AnkyrinG Is Required for Clustering of Voltage-gated Na Channels at Axon Initial Segments and for Normal Action Potential Firing , 1998, The Journal of cell biology.

[107]  S. Hirsch,et al.  Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[108]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[109]  Philip D. Harvey,et al.  Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. , 1998, The American journal of psychiatry.

[110]  T. Woo,et al.  A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[111]  P. Goldman-Rakic,et al.  Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.

[112]  K. Davis,et al.  Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. , 1997, Archives of general psychiatry.

[113]  P. Huttenlocher,et al.  Regional differences in synaptogenesis in human cerebral cortex , 1997, The Journal of comparative neurology.

[114]  L. Glantz,et al.  Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. , 1997, Archives of general psychiatry.

[115]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[116]  T. Woo,et al.  Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. , 1997, The American journal of psychiatry.

[117]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[118]  N. Perrone-Bizzozero,et al.  Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  P. Somogyi,et al.  Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[120]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[121]  B. Moghaddam,et al.  NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[122]  D. Rosenberg,et al.  Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis , 1995, The Journal of comparative neurology.

[123]  J. S. Lund,et al.  Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex , 1995, Neuroscience.

[124]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[125]  Jane S. Paulsen,et al.  Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. , 1994, Archives of General Psychiatry.

[126]  Françoise Condé,et al.  Local circuit neurons immunoreactive for calretinin, calbindin D‐28k or parvalbumin in monkey prefronatal cortex: Distribution and morphology , 1994, The Journal of comparative neurology.

[127]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[128]  R. Gur,et al.  Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. , 1994, Archives of general psychiatry.

[129]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[130]  D. Pickar,et al.  National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. , 1991, Archives of general psychiatry.

[131]  B. Bogerts,et al.  A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. , 1983, Biological psychiatry.

[132]  D. Kavanagh,et al.  Substance Misuse in Patients with Schizophrenia , 2012, Drugs.

[133]  Wei Zhang,et al.  Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia , 2009, Neuropsychopharmacology.

[134]  Nitin Gogtay,et al.  Brain Neuroplasticity in Healthy, Hyperactive and Psychotic Children: Insights from Neuroimaging , 2008, Neuropsychopharmacology.

[135]  D. Lewis,et al.  Neuroplasticity of Neocortical Circuits in Schizophrenia , 2008, Neuropsychopharmacology.

[136]  T. Insel,et al.  Cure therapeutics and strategic prevention: raising the bar for mental health research , 2006, Molecular Psychiatry.

[137]  David A Lewis,et al.  GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. , 2005, Current neuropharmacology.

[138]  C. Carter,et al.  A specific deficit in context processing in the unaffected siblings of patients with schizophrenia. , 2003, Archives of general psychiatry.

[139]  William Byne,et al.  Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. , 2002, The American journal of psychiatry.

[140]  B. Pakkenberg,et al.  No deficit in total number of neurons in the prefrontal cortex in schizophrenics. , 2001, Journal of psychiatric research.

[141]  D. Lewis,et al.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. , 2000, Archives of general psychiatry.

[142]  T. Goldberg,et al.  Cognitive impairment in schizophrenia is the core of the disorder. , 2000, Critical reviews in neurobiology.

[143]  Karl J. Friston,et al.  Schizophrenia: a disconnection syndrome? , 1995, Clinical neuroscience.

[144]  P S Goldman-Rakic,et al.  Synaptogenesis in the prefrontal cortex of rhesus monkeys. , 1994, Cerebral cortex.